Assessment of KAN-101 in Celiac Disease (ACeD) Study Open
The ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingThe ACeD Study is looking for volunteers with celiac disease to participate in a phase 1 clinical trial testing the investigational drug KAN-101.
Continue ReadingThe first mice with characteristics of celiac disease have been developed at the University of Chicago Celiac Disease Center. For the first time researchers can observe celiac disease onset as the mouse’s immune system launches a coordinated attack against gluten.
Continue ReadingResults from a new study suggest that cell immunity in the bowel is irreversibly altered by celiac disease. Early diagnosis and treatment of celiac disease may be able to save some of these beneficial cells and prevent additional permanent damage.
Continue Reading